Citations

Clear

9383 citation(s) found for "Thomas, PS".

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma
Szlosarek, Peter W. , Creelan, Ben , Sarkodie, Thomas, Nolan, Luke, Olevsky, Olga, Grosso, Federica , Roy, Amy, Gilligan, David , Kindler, Hedy L. , Papadatos-Pastos, Dionysis, O’Byrne, Kenneth J. , Nowak, Anna K. , Steele, Jeremy, Sheaff, Michael , Shiu, Chiung‐Fang, Kuo, Chih‐Ling, Johnston, Amanda , Group, ATOMIC-Meso Study, Mackean, Melanie , Steele, Nicola , Upadhyay, Sunil , Srivastav, Ratnesh Kumar , Mencoboni, Manlio, Zilembo, Nicoletta, Marinis, Filippo de , Stella, Maria Giulia, Wang, Chin‐Chou , Nowak, Anna K , Taylor, Paul D. , Cortinovis, Diego Luigi , Chitnis, Meenali M. , Ceresoli, Giovanni Luca , Mansfield, Aaron S. , Tsao, Anne S. , Bomalaski, John S. , Zauderer, Marjorie G. , Fennell, Dean Anthony , Group, ATOMIC-Meso Study, Rybkin, Igor I. , Rolfo, Christian , Franks, K. , Shaw, Paul Nicholas , Lind, Michael , John, Thomas , Karapetis, Christos Stelios , Chella, Antonio , Stella, Maria Giulia, Chong, Inn‐Wen

Mayo Clinic

JAMA Oncology | February 15, 2024 | Volume: 10 | Issue: 4 | Pages: 475

10.1001/jamaoncol.2023.6789 | PMID 38358753 Get It

ImportanceArginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces Cytotoxicity-Mesothelioma) is a pivotal trial comparing standard first-line chemotherapy plus pegargiminase or placebo in patients with nonepithelioid pleural mesothelioma.ObjectiveTo determine the effect of pegargiminase-based chemotherapy on survival in nonepithelioid pleural mesothelioma, an arginine-auxotrophic tumor.Design, Setting, and ParticipantsThis was a phase 2-3, double-blind randomized clinical trial conducted at 43 centers in 5 countries that included patients with chemotherapy-naive nonepithelioid pleural mesothelioma from August 1, 2017, to August 15, 2021, with at least 12 months’ follow-up. Final follow-up was on August 15, 2022. Data analysis was performed from March 2018 to June 2023.InterventionPatients were randomly assigned (1:1) to receive weekly intramuscular pegargiminase (36.8 mg/m2) or placebo. All patients received intravenous pemetrexed (500 mg/m2) and platinum (75-mg/m2 cisplatin or carboplatin area under the curve 5) chemotherapy every 3 weeks up to 6 cycles. Pegargiminase or placebo was continued until progression, toxicity, or 24 months.Main Outcomes and MeasuresThe primary end point was overall survival, and secondary end points were progression-free survival and safety. Response rate by blinded independent central review was assessed in the phase 2 portion only.ResultsAmong 249 randomized patients (mean [SD] age, 69.5 [7.9] years; 43 female individuals [17.3%] and 206 male individuals [82.7%]), all were included in the analysis. The median overall survival was 9.3 months (95% CI, 7.9-11.8 months) with pegargiminase-chemotherapy as compared with 7.7 months (95% CI, 6.1-9.5 months) with placebo-chemotherapy (hazard ratio [HR] for death, 0.71; 95% CI, 0.55-0.93; P = .02). The median progression-free survival was 6.2 months (95% CI, 5.8-7.4 months) with pegargiminase-chemotherapy as compared with 5.6 months (95% CI, 4.1-5.9 months) with placebo-chemotherapy (HR, 0.65; 95% CI, 0.46-0.90; P = .02). Grade 3 to 4 adverse events with pegargiminase occurred in 36 patients (28.8%) and with placebo in 21 patients (16.9%); drug hypersensitivity and skin reactions occurred in the experimental arm in 3 patients (2.4%) and 2 patients (1.6%), respectively, and none in the placebo arm. Rates of poststudy treatments were comparable in both arms (57 patients [45.6%] with pegargiminase vs 58 patients [46.8%] with placebo).Conclusions and RelevanceIn this randomized clinical trial of arginine depletion with pegargiminase plus chemotherapy, survival was extended beyond standard chemotherapy with a favorable safety profile in patients with nonepithelioid pleural mesothelioma. Pegargiminase-based chemotherapy as a novel antimetabolite strategy for mesothelioma validates wider clinical testing in oncology.Trial RegistrationClinicalTrials.gov Identifier: NCT02709512
Evaluation of Intracardiac Pressures Using Subharmonic-aided Pressure Estimation with Sonazoid Microbubbles
Esposito, Cara , Machado, Priscilla , McDonald, Maureen E. , Savage, Michael P. , Fischman, David L. , Mehrotra, Praveen , Cohen, Ira S. , Ruggiero, Nicholas , Walinsky, Paul, Vishnevsky, Alec, Dickie, Kristopher, Davis, Marguerite , Forsberg, Flemming , Dave, Jaydev K. , Fischman, David

Mayo Clinic

Radiology: Cardiothoracic Imaging | February 15, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1148/ryct.230153 | PMID 38358329 Get It

Biliary Disorders, Anomalies, and Malignancies in Children
Simmons, Curtis , Harper, Laura K , Patel, Mittun C. , Katabathina, Venkat S. , Southard, Richard , Gonçalves, Luís F. , Tran, Evelyn , Biyyam, Deepa R. , Simmons, Curtis L , Southard, Richard N , Goncalves, Luis

Mayo Clinic

RadioGraphics | February 15, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1148/rg.230109 | PMID 38358937 Get It

Proceed with caution: Standard protocol exercise stress tests fail to replicate the diagnostic utility of supine‐stand tests for long QT syndrome
Pinsky, Alexa M. , Kulkarni, Veda, Bos, J. Martijn , Allison, Thomas G. , Ackerman, Michael J. , Kulkarni, Veda K, Bos, Johan M , Neves, Raquel

Mayo Clinic

Pacing and Clinical Electrophysiology | February 13, 2024 | Volume: 47 | Issue: 3 | Pages: 455-461

10.1111/pace.14945 | PMID 38348899 Get It

AbstractBackgroundLong QT syndrome (LQTS) is a sudden death predisposing condition characterized by ECG‐derived prolongation of the QT interval. Previous studies have demonstrated that the supine‐stand test may aid in the diagnosis of LQTS as patients fail to shorten their QT interval in response to standing up. The aim of this study was to evaluate the diagnostic accuracy of ECG data derived from standard protocol, clinically performed treadmill exercise stress tests (TESTs) in their ability to mimic the formal supine‐stand test.MethodsWe performed a retrospective review of 478 TESTs from patients evaluated for LQTS. Patients referred for evaluation of LQTS but who were dismissed as normal served as controls. Heart rate & QT values were obtained from standard protocol TESTs.ResultsOverall, 243 patients with LQTS (125 LQT1, 63 LQT2, 55 LQT3; 146 [60%] female, mean age at TEST 30 ± 17 years) and 235 controls (142 [60%] female, mean age 24 ± 15 years) were included. The paired ΔQTc (QTcStand‐QTcSupine) was similar between LQTS (−5 ± 26) and controls (−2 ± 25; p = .2). During position change, the QT interval shortened by ≥20 ms in 33% of LQTS patients, remained unchanged in 62%, and increased in 5% of LQTS patients which was similar to controls (shortened in 40%, unchanged in 54%, and increased in 6% of controls; p = .2). Receiver‐operator curve analysis to test the diagnostic ability of supine‐stand ΔQT performed poorly in differentiating LQTS from controls with an of AUC 0.52 (p = .4).ConclusionTESTs should be used with caution when trying to interpret supine‐stand changes for diagnosis of LQTS.
Graduate training, credentialing, and continuing education to prepare genetic counselors for laboratory roles—Results of a national survey
Schwartz, Lisa , Mackall, Mia S. , Arjunan, Aishwarya , Goodenberger, McKinsey L. , Mills, Rachel , Ham, C. , Witherington, Sarah , Goodenberger, McKinsey , Ham, Chloe , Arjunan, Aishwarya , Witherington, Sarah , Mills, Rachel

Mayo Clinic

Journal of Genetic Counseling | February 10, 2024 | Volume: 34 | Issue: 1 | Pages: No page available

10.1002/jgc4.1883 | PMID 38339832 Get It

Abstract Opportunities for genetic counselors to work in a variety of practice settings have greatly expanded, particularly in the laboratory. This study aimed to assess attitudes of genetic counselors working both within and outside of the laboratory setting regarding (1) the re‐wording and/or expansion of key measures of genetic counselors' competency, including practice‐based competencies (PBCs) and board examination, to include laboratory roles, (2) preparation and transferability of competencies developed in master's in genetic counseling (MGC) programs to different roles, (3) need of additional training for genetic counselors to practice in laboratory settings, and (4) preferred methods to obtain that training. An e‐blast was sent to ABGC diplomats ( N = 5458) with a link to a 29‐item survey with 12 demographic questions to compare respondents to 2021 NSGC Professional Status Survey (PSS) respondents. Statistical comparisons were made between respondents working in the laboratory versus other settings. Among 399 responses received, there was an oversampling of respondents working in the laboratory (52% vs. 20% in PSS) and in non‐direct patient care positions (47% vs. 25% in PSS). Most respondents agreed the PBCs were transferable to their work yet favored making the PBCs less direct patient care‐focused, expanding PBCs to align with laboratory roles, adding laboratory‐focused questions to the ABGC exam, and adding laboratory‐focused training in MGC programs. Most agreed requiring post‐MGC training would limit genetic counselors' ability to change jobs. Genetic counselors working in the laboratory reported being significantly less prepared by their MGC program for some roles ( p < 0.001) or how the PBCs applied to non‐direct patient care positions ( p < 0.001). Only 53% of all respondents agreed that NSGC supports their professional needs and others in their practice area, and genetic counselors working in the laboratory were significantly less likely to agree ( p = 0.002). These sentiments should be further explored.
Core outcomes in nerve surgery: development of a core outcome set for brachial plexus and upper extremity nerve injuries
Wilson, Thomas J. , Ali, Zarina S. , Davis, Gavin A , Desai, Ketan, Garozzo, Debora, Guedes, Fernando , Jack, Megan M. , Jacques, Line , Kretschmer, Thomas , Midha, Rajiv, Puffer, Ross C. , Rasulić, Lukas , Ray, Wilson Z. , Rizk, Elias , Rodríguez-Aceves, Carlos Alberto , Shapira, Yuval, Spinner, Robert J. , Zager, Eric L. , Davis, Gavin A. , Dengler, Nora F. , Mahan, Mark A , Pondaag, Willem , Smith, Brandon W. , Socolovsky, Mariano

Mayo Clinic

Journal of Neurosurgery | February 9, 2024 | Volume: 141 | Issue: 2 | Pages: 474-483

10.3171/2023.11.jns232272 | PMID 38335525 Get It

OBJECTIVE When considering traumatic brachial plexus and upper extremity nerve injuries, iatrogenic nerve injuries, and nontraumatic nerve injuries, brachial plexus and upper extremity nerve injuries are commonly encountered in clinical practice. Despite this, data synthesis and comparison of available studies are difficult. This is at least in part due to the lack of standardization in reporting and a lack of a core outcome set (COS). Thus, there is a need for a COS for adult brachial plexus and upper extremity nerve injuries (COS-BPUE). The objective of this study was to develop a COS-BPUE using a modified Delphi approach. METHODS A 5-stage approach was used to develop the COS-BPUE: 1) consortium development, 2) literature review to identify potential outcome measures, 3) Delphi survey to develop consensus on outcomes for inclusion, 4) Delphi survey to develop definitions, and 5) consensus meeting to finalize the COS and definitions. The study followed the Core Outcome Set-STAndards for Development (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 23 participants, all neurological surgeons, representing 13 countries. The final COS-BPUE consisted of 36 data points/outcomes covering demographic, diagnostic, patient-reported outcome, motor/sensory outcome, and complication domains. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 24 months, with the consensus optimal time points for assessment being preoperatively and 3, 6, 12, and 24 months postoperatively. CONCLUSIONS The COINS Consortium developed a consensus COS and provided definitions, methods of implementation, and time points for assessment. The COS-BPUE should serve as a minimum set of data that should be collected in all future neurosurgical studies on adult brachial plexus and upper extremity nerve injuries. Incorporation of this COS should help improve consistency in reporting, data synthesis, and comparability, and should minimize outcome reporting bias.
External Validation of the 2023 Duke–International Society for Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis
Vaart, Thomas W. van der , Durack, David T., Karchmer, Adolf W. , Moreillon, Philippe, Selton‐Suty, Christine , Fowler, Vance G. , Meer, Jan T. M. van der, van der Vaart, Thomas W , Rasmussen, Magnus , Selton-Suty, Christine , Bossuyt, Patrick M. , Baddour, Larry M. , Bayer, Arnold S. , Durante‐Mangoni, Emanuele , Holland, Thomas L , Miró, José María , Fowler, Vance G.

Mayo Clinic

Clinical Infectious Diseases | February 8, 2024 | Volume: 78 | Issue: 4 | Pages: 922-929

10.1093/cid/ciae033 | PMID 38330166 Get It

Abstract Background The 2023 Duke–International Society of Cardiovascular Infectious Diseases (ISCVID) criteria for infective endocarditis (IE) were introduced to improve classification of IE for research and clinical purposes. External validation studies are required. Methods We studied consecutive patients with suspected IE referred to the IE team of Amsterdam University Medical Center (from October 2016 to March 2021). An international expert panel independently reviewed case summaries and assigned a final diagnosis of “IE” or “not IE,” which served as the reference standard, to which the “definite” Duke-ISCVID classifications were compared. We also evaluated accuracy when excluding cardiac surgical and pathologic data (“clinical” criteria). Finally, we compared the 2023 Duke-ISCVID with the 2000 modified Duke criteria and the 2015 and 2023 European Society of Cardiology (ESC) criteria. Results A total of 595 consecutive patients with suspected IE were included: 399 (67%) were adjudicated as having IE; 111 (19%) had prosthetic valve IE, and 48 (8%) had a cardiac implantable electronic device IE. The 2023 Duke-ISCVID criteria were more sensitive than either the modified Duke or 2015 ESC criteria (84.2% vs 74.9% and 80%, respectively; P &lt; .001) without significant loss of specificity. The 2023 Duke-ISCVID criteria were similarly sensitive but more specific than the 2023 ESC criteria (94% vs 82%; P &lt; .001). The same pattern was seen for the clinical criteria (excluding surgical/pathologic results). New modifications in the 2023 Duke-ISCVID criteria related to “major microbiological” and “imaging” criteria had the most impact. Conclusions The 2023 Duke-ISCVID criteria represent a significant advance in the diagnostic classification of patients with suspected IE.
Variable Return to Play and Sport Performance After Elbow Ulnar Collateral Ligament Reconstruction in Baseball Players: A Systematic Review
Hones, Keegan M. , Kamarajugadda, Sravya , Buchanan, Timothy R. , Portnoff, Brandon , Hao, Kévin A. , Kim, Jongmin , King, Joseph J. , Wright, Thomas W. , Aibinder, William R. , King, Joseph J , Hao, Kevin A , Aibinder, William R , Hones, Keegan M , Wright, Jonathan O. , Schoch, Bradley S.

Mayo Clinic

Arthroscopy | February 8, 2024 | Volume: 40 | Issue: 7 | Pages: 1997

10.1016/j.arthro.2024.01.033 | PMID 38340970 Get It

Purpose To evaluate return to play (RTP) and return to same level of play (RTSP) rates as well as preoperative and postoperative in‐game performance metrics in baseball pitchers who underwent ulnar collateral ligament reconstruction (UCLR). Secondarily, this review sought to assess outcomes based on primary versus revision UCLR as well as level of competition. Methods This review was performed using Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. PubMed/MEDLINE, Embase, Web of Science, and Cochrane Database of Systematic Reviews were queried to identify articles evaluating UCLR in baseball players between January 2002 and October 2022. Data included RTP, RTSP, and performance metrics including earned run average, innings pitched, walks and hits per inning pitched, batting average against, strikeouts per 9 innings, walks per 9 innings, percentage of fastballs thrown, and average fastball velocity. The Methodological Index for Non‐randomized Studies criteria were used for quality assessment. Results Analysis included 25 articles reporting on 2,100 elbows. After primary UCLR, RTP ranged from 336 to 615 days (57% to 100% achieved) and RTSP ranged from 330 to 513 days (61% to 95%). After revision UCLR, RTP ranged from 381 to 631 days (67% to 98%) and RTSP ranged from 518 to 575 days (42% to 78%). When stratifying primary UCLR outcomes by competitive level, RTP and RTSP ranged respectively from 417 to 615 days (75% to 100%) and 513 days (73% to 87%) for Major League Baseball only, 409 to 615 days (57% to 100%) and 470 to 513 days (61% to 95%) for Major League Baseball plus Minor League Baseball, and 336 to 516 days (73% to 85%) and 330 days (55% to 74%) for college plus high school. Heterogeneity was seen in postoperative sports performance metrics. Conclusions Although more than half of baseball players appear able to RTP after primary and revision UCLR, RTSP rates after revision UCLR were as low as 42% in the literature. Preoperative and postoperative performance metrics varied. Level of Evidence Level IV, systematic review of Level II‐IV studies.
Spike ripples localize the epileptogenic zone best: an international intracranial study
Shi, Wen , Shaw, Dana , Walsh, Katherine G. , Han, Xue , Eden, Uri T. , Gliske, S. , Jacobs, Julia , Brinkmann, Benjamin H. , Worrell, Gregory A. , Kramer, Mark , Chu, Catherine J. , Gliske, Stephen V , Brinkmann, Benjamin H , Worrell, Gregory A , Kramer, Mark A , Chu, Catherine J , Richardson, Robert Mark , Stacey, William C. , Frauscher, Birgit , Thomas, John Paul

Mayo Clinic

Brain | February 7, 2024 | Volume: 147 | Issue: 7 | Pages: 2496-2506

10.1093/brain/awae037 | PMID 38325327 Get It

Abstract We evaluated whether spike ripples, the combination of epileptiform spikes and ripples, provide a reliable and improved biomarker for the epileptogenic zone compared with other leading interictal biomarkers in a multicentre, international study. We first validated an automated spike ripple detector on intracranial EEG recordings. We then applied this detector to subjects from four centres who subsequently underwent surgical resection with known 1-year outcomes. We evaluated the spike ripple rate in subjects cured after resection [International League Against Epilepsy Class 1 outcome (ILAE 1)] and those with persistent seizures (ILAE 2–6) across sites and recording types. We also evaluated available interictal biomarkers: spike, spike-gamma, wideband high frequency oscillation (HFO, 80–500 Hz), ripple (80–250 Hz) and fast ripple (250–500 Hz) rates using previously validated automated detectors. The proportion of resected events was computed and compared across subject outcomes and biomarkers. Overall, 109 subjects were included. Most spike ripples were removed in subjects with ILAE 1 outcome (P &lt; 0.001), and this was qualitatively observed across all sites and for depth and subdural electrodes (P &lt; 0.001 and P &lt; 0.001, respectively). Among ILAE 1 subjects, the mean spike ripple rate was higher in the resected volume (0.66/min) than in the non-removed tissue (0.08/min, P &lt; 0.001). A higher proportion of spike ripples were removed in subjects with ILAE 1 outcomes compared with ILAE 2–6 outcomes (P = 0.06). Among ILAE 1 subjects, the proportion of spike ripples removed was higher than the proportion of spikes (P &lt; 0.001), spike-gamma (P &lt; 0.001), wideband HFOs (P &lt; 0.001), ripples (P = 0.009) and fast ripples (P = 0.009) removed. At the individual level, more subjects with ILAE 1 outcomes had the majority of spike ripples removed (79%, 38/48) than spikes (69%, P = 0.12), spike-gamma (69%, P = 0.12), wideband HFOs (63%, P = 0.03), ripples (45%, P = 0.01) or fast ripples (36%, P &lt; 0.001) removed. Thus, in this large, multicentre cohort, when surgical resection was successful, the majority of spike ripples were removed. Furthermore, automatically detected spike ripples localize the epileptogenic tissue better than spikes, spike-gamma, wideband HFOs, ripples and fast ripples.
Genome-wide association analysis identifies PLA2G4C as a susceptibility locus for Multiple System Atrophy
Tsuji, Shoji , Nakahara, Yasuo , Mitsui, Jun , Date, Hidetoshi, Porto, Kristine Joyce L. , Hyashi, Y., Kusakabe, Yoshio , Matsukawa, Takashi , Ishiura, Hiroyuki , Yasuda, Tsutomu , Goto, Jun , Ichikawa, Yaeko, Momose, Yoshio, Takahashi, Yuji , Ohta, Rikifumi , Yoshimura, Jun , Gustavsson, Emil K. , Christy, Darren, Maczis, Melisa, Gu, Weihong, Scholz, Sonja W. , Houlden, Henry , Sasaki, Hidenao , Kikuchi, Akio , Hara, Kenju , Kakita, Akiyoshi , Yamada, Mitsunori , Nishizawa, Masatoyo , Ito, Mizuki , Sobue, Gen , Ishikawa, Kinya , Mizusawa, Hidehiro, Kanai, Kazuaki , Arai, Kimihito , Koyano, Shigeru , Kuroiwa, Yoshiyuki , Hasegawa, Kazuko, Yuasa, Tatsuhiko, Yasui, Kenichi, Ito, Hijiri, Izumi, Yuishin , Kaji, Ryuji , Kato, Takeo , Kusunoki, Susumu , Osaki, Yasushi , Horiuchi, Masahiro , Yamamoto, Ken , Shimada, Mihoko , Miyagawa, Taku , Nishida, Nao , Tokunaga, Katsushi , Filla, Alessandro , Klockgether, Thomas , Wuellner, Ullrich, Kukull, Walter A. , Masliah, Eliezer , Low, Phillip A. , Sandroni, Paola , Ozelius, Laurie J. , Trojanowski, John Q. , Scholz, Sonja W , Houlden, Henry , Yamashita, Atsushi , Yasuda, Tsutomu, Iwata, Atsushi , Toda, Tatsushi , Morishita, Shinichi , Kim, Han‐Joon , Park, Sung Sup , Zhang, Jin , Chelban, Viorica , Mok, Kin Ying , Yabe, Ichiro , Matsushima, Masaaki , Takashima, Hiroshi , Aoki, Masashi , Takahashi, Hitoshi , Onodera, Osamu , Watanabe, Hirohisa , Kuwabara, Satoshi , Nakashima, Kenji , Horiuchi, Masahiro, Kawai, Yosuke , Dürr, Alexandra , Brice, Alexis , Tanner, Caroline M. , Lee, Virginia M.‐Y. , Foroud, Tatiana , Farrer, Matthew J.

Mayo Clinic

No container title available | February 6, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3461290/v1 Get It

Abstract To elucidate the molecular basis of multiple system atrophy (MSA), a neurodegenerative disease, we conducted a genome-wide association study (GWAS) in a Japanese MSA case/control series followed by replication studies in Japanese, Korean, Chinese, European, and North American samples. In the GWAS stage, rs2303744 on chromosome 19 showed a suggestive association (P = 6.5 × 10− 7) that was replicated in additional Japanese samples (P = 2.9 × 10− 6, odds ratio (OR) = 1.58; 95% confidence interval (CI), 1.30–1.91), and then confirmed as highly significant in a meta-analysis of East Asian population data (P = 5.0 × 10− 15, OR = 1.49; 95% CI 1.35–1.65). The association of rs2303744 with MSA remained significant in combined European/North American samples (P = 0.017, OR = 1.12; 95% CI 1.02–1.23) despite allele frequencies being quite different between these populations. rs2303744 leads to an amino acid substitution in PLA2G4C that encodes the cPLA2γ lysophospholipase/transacylase. The cPLA2γ-Ile143 isoform encoded by the MSA risk allele has significantly decreased transacylase activity compared with the alternate cPLA2γ-Val143 isoform, and may perturb membrane phospholipids and promote oligodendroglial pathology.